用LDH酶辅助的高性能现场追踪莱沃多巴的药理动力学,用于帕金森病的管理
Da-Wei Zhou1, Meng Yin1, Yun Shen2
1Lab of Functional and Biomedical Nanomaterials, College of Materials Science and Engineering, Qingdao University of Science and Technology (QUST), Qingdao, 266042, PR China.
Biosensors & bioelectronics
|November 13, 2024
概括
一个新的CuCoFe-LDHzyme汗液传感器为帕金森病 (PD) 患者提供了对levodopa的实时,非侵入性监测. 这一突破使精确的药物调整成为可能,提高了治疗效率和患者的生活质量.
科学领域:
- 生物医学工程 生物医学工程
- 神经科学是一个神经科学.
- 分析化学 分析化学
背景情况:
- 帕金森病 (PD) 涉及渐进的神经退行,影响运动和认知功能.
- 利沃多巴是主要的治疗方法,但由于其狭窄的治疗窗口和复杂的药理动力学,需要精确的剂量.
- 目前的监测依赖于侵入性血液采样,限制实时治疗调整.
研究的目的:
- 开发一种基于CuCoFe-LDH酶的新型传感器,用于对帕金森病患者进行非侵入性,实时的勒沃多巴监测.
- 为了确定汗水中的勒沃多巴度与血液中的勒沃多巴水平之间的相关性.
- 为优化莱沃多巴剂量和个性化治疗方案提供一个工具.
主要方法:
- 基于CuCoFe-LDH酶的电化学传感器的开发.
- 使用微分脉冲电压测量 (DPV) 来检测莱沃多巴.
- 实施pH值校正,以准确量化汗液中的乐伏多巴,并与血液水平相关联.
主要成果:
- 传感器在勒沃多巴检测方面实现了高灵敏度和选择性,检测极限为28.1nM.
- 在汗水和血液中莱沃多巴度之间显示出强烈的相关性 (皮尔森系数=0.833).
- 在PD患者中成功重建了勒沃多巴的实时药动力学概况.
结论:
- CuCoFe-LDHzyme汗液传感器可以方便,非侵入性,实时监测利沃多巴.
- 这项技术促进了帕金森病的个性化治疗策略.
- 该传感器具有显著的潜力,可以改善药物管理和PD患者的治疗结果.
相关概念视频
Parkinson's Disease: Treatment
222
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
222
Parkinson's Disease: Overview
482
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
482


